Telomir confirms copper binding capabilities of Telomir-1

Telomir Pharmaceuticals (TELO) announced findings from its copper binding studies with Telomir-1. The company said, “This is a promising development as the company explores Telomir-1 for the treatment of Wilson’s disease and other copper related disorders. The announcement marks an important step forward in Telomir’s mission to address critical unmet medical needs while continuing to explore transformative therapies. Recent preclinical in vitro studies conducted by Recipharm and Smart Assays have demonstrated Telomir-1’s exceptional binding affinity for copper ions, highlighting its ability to selectively interact with and regulate copper metabolism. Additionally, Telomir-1’s capability to bind and exchange key ions, including copper, iron, and zinc, emphasizes its unique profile and positions it as a promising candidate for further research. These findings form a strong foundation for investigating Telomir-1’s potential in addressing Wilson’s disease, a rare genetic disorder characterized by excessive copper accumulation that can result in significant damage to the liver, brain, and other vital organs.” Earlier this year, Telomir partnered with Midwest Veterinary Services to launch a planned large-scale study on osteoarthritis in dogs. While only the safety phase of the study was completed-showing no adverse effects-the Company chose to discontinue the study. This decision was based on the requirement to induce osteoarthritis in the dogs, a practice that conflicted with the new management’s commitment to the Company’s mission and values. Instead, the Company is now in discussions with a well-known veterinary institution to design a new study that will recruit elderly dogs who naturally suffer from osteoarthritis. As such, Telomir is committed to obtaining an Investigational New Animal Drug application for pets while progressing toward an IND Investigational New Drug application for humans. The company said, “As we continue to gather scientific data and delve deeper into the molecular mechanisms of action of Telomir-1, we are positioning ourselves to identify the most impactful indication for our initial IND application. The Company is currently working on the optimization of manufacturing processes to enable an affordable and scalable approach. This will support the production of GMP-grade quantities necessary for IND-enabling studies and clinical trials. The Company plans to carry out the IND-enabling safety studies in Q2 2025, targeting IND submission by Q4 2025, with first-in-human clinical trials anticipated in the first half of 2026. The company also plans to secure an INAD for pets, paving the way for Telomir-1’s dual application in both human and veterinary medicine.”